RNA Genetic Testing Improves Analysis of Hereditary Cancer Genes

MedicalResearch.com Interview with:
Rachid Karam, PhD

Director, Ambry Translational Genomics Lab
Ambry Genetics 

MedicalResearch.com: What is the background for this study?

Response: DNA genetic testing (DGT) for hereditary cancer genes is now a well accepted clinical practice; however, the interpretation of DNA variation remains a challenge to laboratories and medical providers.

RNA genetic testing (RGT) as a supplement to DGT is a means to clarify the clinical actionability of variants in hereditary cancer genes, improving our ability to accurately apply known strategies for cancer risk reduction.

Continue reading